Conference Proceedings
Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)
L Mileshkin, E Barnes, KN Moore, V Gebski, M King, K Narayan, IK Kolodziej, K Sjoquist, A Fyles, W Small, D Gaffney, M Quinn, J Andrews, S Thompson, W Huh, M Carlson, PA Disilvestro, D Rischin, MR Stockler, BJ Monk
ANNALS OF ONCOLOGY | ELSEVIER | Published : 2019
Abstract
Background OUTBACK is testing the addition of 4 cycles of adjuvant carboplatin/paclitaxel chemotherapy (chemo) after definitive chemoradiation in locally advanced cervix cancer. We aimed to determine characteristics associated with not starting randomly assigned adjuvant chemo. Methods We assessed associations between not starting assigned adjuvant chemo and baseline characteristics of: age; race; country; smoking status; ECOG; BMI; FIGO stage; node involvement; and participants’ self-rated physical, role, emotional, cognitive, social functional status, and financial difficulties (by EORTC QLQ-C30). We also assessed for associations with completion of chemoradiation and grade 3-4 toxicities ..
View full abstractGrants
Funding Acknowledgements
National Health and Medical Research Council. In addition, Hospira provided paclitaxel treatment for Australian and New Zealand patients in the study.